ORCID Profile
0000-0002-0671-3103
Current Organisations
York University
,
Airlangga University
,
University of Queensland
Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.
Publisher: Research Square Platform LLC
Date: 04-11-2020
DOI: 10.21203/RS.3.RS-29038/V3
Abstract: Background: Clinical whole exome sequencing was introduced in an Australian centre in 2017, as an alternative to Sanger sequencing. We aimed to identify predictors of cancer physicians’ somatic mutation test ordering behaviour. Methods: A validated instrument assessed somatic mutation test ordering, genomic confidence, perceived utility of tumour molecular profiling, and percent of patients eligible for targeted therapy. A cash incentive was included in 189/244 questionnaires which were mailed to all Queensland cancer specialists in November 2018. Results: 110 participated (response rate 45%) 54.7% oncologists, and the remainder were surgeons, haematologists and pulmonologists. Oncologists were more likely to respond (p=0.008), and cash incentive improved the response rate (p .001). 67/102 (65.7%) of physicians ordered ≥5 somatic mutation tests annually. Oncologists saw 86.75 unique patients monthly and ordered 2.33 somatic mutation tests (2.2%). An average of 51/110 (46.1%) reported having little/no genomic confidence. Logistic regression identified two significant predictors of somatic mutation test ordering: being an oncologist (OR 3.557, CI 1.338-9.456 p=0.011) and having greater confidence in interpreting somatic results (OR 5.926, CI 2.230-15.74 p .0001). Conclusions: Consistent with previous studies, the majority of cancer physicians ordered somatic mutation tests. However, the percentage of patients on whom tests were ordered was low. Almost half respondents reported low genomic confidence. Somatic mutation test ordering was higher amongst oncologists and those with increased confidence in interpreting somatic variants. It is unclear whether genomically confident in iduals ordered more tests or whether ordering more tests increased genomic confidence. Educational interventions could improve confidence and enhance test ordering behaviour.
Publisher: Research Square Platform LLC
Date: 14-10-2020
DOI: 10.21203/RS.3.RS-29038/V2
Abstract: Background: Clinical whole exome sequencing was introduced in an Australian centre in 2017, as an alternative to Sanger sequencing. We aimed to identify predictors of cancer physicians’ somatic mutation test ordering behaviour. Methods: A validated instrument assessed somatic mutation test ordering, genomic confidence, perceived utility of tumour molecular profiling, and percent of patients eligible for targeted therapy. A cash incentive was included in 189/244 questionnaires which were mailed to all Queensland cancer specialists in November 2018. Results: 110 participated (response rate 45%) 54.7% oncologists, and the remainder were surgeons, haematologists and pulmonologists. Oncologists were more likely to respond (p=0.008), and cash incentive improved the response rate (p .001). 67/102 (65.7%) of physicians ordered ≥5 somatic mutation tests annually. Oncologists saw 86.75 unique patients monthly and ordered 2.33 somatic mutation tests (2.2%). An average of 51/110 (46.1%) reported having little/no genomic confidence. Logistic regression identified two significant predictors of somatic mutation test ordering: being an oncologist (OR 3.557, CI 1.338-9.456 p=0.011) and having greater confidence in interpreting somatic results (OR 5.926, CI 2.230-15.74 p .0001). Conclusions: Consistent with previous studies, the majority of cancer physicians ordered somatic mutation tests. However, the percentage of patients on whom tests were ordered was low. Almost half respondents reported low genomic confidence. Somatic mutation test ordering was higher amongst oncologists and those with increased confidence in interpreting somatic variants. It is unclear whether genomically confident in iduals ordered more tests or whether ordering more tests increased genomic confidence. Educational interventions could improve confidence and enhance test ordering behaviour.
Publisher: Research Square Platform LLC
Date: 27-05-2020
DOI: 10.21203/RS.3.RS-29038/V1
Abstract: Background: Clinical whole exome sequencing was introduced in an Australian centre in 2017, as an alternative to Sanger sequencing. We aimed to identify predictors of cancer physicians’ somatic mutation test ordering behaviour. Methods: A validated instrument assessed somatic mutation test ordering, genomic confidence, perceived utility of tumour molecular profiling, and percent of patients eligible for targeted therapy. A cash incentive was included in 189/244 questionnaires which were mailed to all Queensland cancer specialists in November 2018. Results: 110 participated (response rate 45%) 54.7% oncologists, and the remainder were surgeons, haematologists and pulmonologists. Oncologists were more likely to respond (p = 0.008), and cash incentive improved the response rate (p 0.001). 67/102 (65.7%) of physicians ordered ≥ 5 somatic mutation tests annually. Oncologists saw 86.75 unique patients monthly and ordered 2.33 somatic mutation tests (2.2%). An average of 51/110 (46.1%) reported having little/no genomic confidence. Logistic regression identified two significant predictors of somatic mutation test ordering: being an oncologist (OR 3.557, CI 1.338–9.456 p = 0.011) and having greater confidence in interpreting somatic results (OR 5.926, CI 2.230–15.74 p 0.0001). Conclusions: Consistent with previous studies, the majority of cancer physicians ordered somatic mutation tests. However, the percentage of patients on whom tests were ordered was low. Almost half respondents reported low genomic confidence. Somatic mutation test ordering was higher amongst oncologists and those with increased confidence in interpreting somatic variants. It is unclear whether genomically confident in iduals ordered more tests or whether ordering more tests increased genomic confidence. Educational interventions could improve confidence and enhance test ordering behaviour.
Publisher: Elsevier BV
Date: 10-2022
Publisher: Oxford University Press (OUP)
Date: 05-03-2023
DOI: 10.1093/BJD/LJAD041
Abstract: Population-wide screening for melanoma is not cost-effective, but genetic characterization could facilitate risk stratification and targeted screening. Common Melanocortin-1 receptor (MC1R) red hair colour (RHC) variants and Microphthalmia-associated transcription factor (MITF) E318K separately confer moderate melanoma susceptibility, but their interactive effects are relatively unexplored. To evaluate whether MC1R genotypes differentially affect melanoma risk in MITF E318K+ vs. E318K– in iduals. Melanoma status (affected or unaffected) and genotype data (MC1R and MITF E318K) were collated from research cohorts (five Australian and two European). In addition, RHC genotypes from E318K+ in iduals with and without melanoma were extracted from databases (The Cancer Genome Atlas and Medical Genome Research Bank, respectively). χ2 and logistic regression were used to evaluate RHC allele and genotype frequencies within E318K+/– cohorts depending on melanoma status. Replication analysis was conducted on 200 000 general-population exomes (UK Biobank). The cohort comprised 1165 MITF E318K– and 322 E318K+ in iduals. In E318K– cases MC1R R and r alleles increased melanoma risk relative to wild type (wt), P & 0.001 for both. Similarly, each MC1R RHC genotype (R/R, R/r, R/wt, r/r and r/wt) increased melanoma risk relative to wt/wt (P & 0.001 for all). In E318K+ cases, R alleles increased melanoma risk relative to the wt allele [odds ratio (OR) 2.04 (95% confidence interval 1.67–2.49) P = 0.01], while the r allele risk was comparable with the wt allele [OR 0.78 (0.54–1.14) vs. 1.00, respectively]. E318K+ cases with the r/r genotype had a lower but not significant melanoma risk relative to wt/wt [OR 0.52 (0.20–1.38)]. Within the E318K+ cohort, R genotypes (R/R, R/r and R/wt) conferred a significantly higher risk compared with non-R genotypes (r/r, r/wt and wt/wt) (P & 0.001). UK Biobank data supported our findings that r did not increase melanoma risk in E318K+ in iduals. RHC alleles/genotypes modify melanoma risk differently in MITF E318K– and E318K+ in iduals. Specifically, although all RHC alleles increase risk relative to wt in E318K– in iduals, only MC1R R increases melanoma risk in E318K+ in iduals. Importantly, in the E318K+ cohort the MC1R r allele risk is comparable with wt. These findings could inform counselling and management for MITF E318K+ in iduals.
Publisher: Institute of Advanced Engineering and Science
Date: 09-2022
DOI: 10.11591/IJEECS.V27.I3.PP1212-1222
Abstract: Rooftop photovoltaic (PV) plant is one ot the independent electricity that us favorable in recent year. Rooftop PV plant can be used as the source of smart building as well as fast charging station. Although rooftop PV plant could provide clean and sustainable energy from solar, they also come with disadvantages in term of intermittent power output. This intermittent power output is due to the uncertainty of the source. To tackle this problem, maximum power point tracking method is essential. Maximum power point tracking (MPPT) method can be used to extract maximum power from the solar cell in all conditions. This paper proposes an intelligent method for designing DC-DC MPPT based on span fruit fly optimization /span (FFO) on realistic rooftop PV plant. Practical rooftop PV plant in Universitas Airlangga is employed as the testing system. The proposed method's efficacy is evaluated using time domain simulation. According to the simulation results, the proposed method can significantly extract power from PV.
No related grants have been discovered for Anastassia Demeshko.